Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Dec 16;5(1):586-96.
doi: 10.1007/s12072-010-9227-x.

Predictors for early HBeAg loss during lamivudine therapy in HBeAg-positive chronic hepatitis B patients with acute exacerbation

Cheng-Yuan Peng, Chih-Bin Chen, Hsueh-Chou Lai, Wen-Pang Su, Po-Heng Chuang, Hong-Dar Isaac Wu, Long-Bin Jeng

Predictors for early HBeAg loss during lamivudine therapy in HBeAg-positive chronic hepatitis B patients with acute exacerbation

Cheng-Yuan Peng et al. Hepatol Int. .

Abstract

Purpose: To examine the rate of early HBeAg loss and predictors of HBeAg loss in HBeAg-positive chronic hepatitis B (CHB) patients with acute exacerbation (AE) treated with lamivudine.

Methods: A total of 146 patients diagnosed with CHB and AEs were included in this retrospective study. Patients were divided into two groups: decompensated and compensated.

Results: The mean treatment duration for the decompensated and compensated groups was 18.1 and 19.9 months, respectively. Decompensated patients were significantly older and had a higher prevalence of cirrhosis and genotype B infection than compensated patients. Compared to compensated patients, decompensated patients achieved a higher rate of HBeAg loss (25.8 vs. 14.3%; P = 0.0805) at 3 months of therapy, a higher rate of serum HBV DNA negativity (53.2 vs. 29.8%; P = 0.0042), and a lower rate of rtM204V/I mutation (3.2 vs. 16.7%; P = 0.0139) after 12 months of lamivudine therapy. The rates of HBeAg loss after 6 and 12 months of lamivudine therapy were similar between the two groups. Logistic regression analysis revealed that female gender and baseline ALT level ≥1,000 IU/L, but not decompensations, were significant predictors of HBeAg loss at 3 months; however, only female gender was a significant predictor of HBeAg loss after 6 and 12 months of lamivudine therapy. The early HBeAg losers showed a significantly higher sustained remission rate off lamivudine therapy.

Conclusions: Female gender and baseline serum ALT level ≥1,000 IU/L were independent predictors of early HBeAg loss during lamivudine therapy in HBeAg-positive CHB patients with AE.

Electronic supplementary material: The online version of this article (doi:10.1007/s12072-010-9227-x) contains supplementary material, which is available to authorized users.

Keywords: Acute exacerbation; Chronic hepatitis B; Decompensation; HBeAg loss; Lamivudine.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis. 2003;23:47–58. doi: 10.1055/s-2003-37590. - DOI - PubMed
    1. Chu CM, Liaw YF. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepat. 2007;14:147–152. doi: 10.1111/j.1365-2893.2006.00810.x. - DOI - PubMed
    1. Liaw YF. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol. 2003;18:246–252. doi: 10.1046/j.1440-1746.2003.02976.x. - DOI - PubMed
    1. Sheen IS, Liaw YF, Tai DI, et al. Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis. Gastroenterology. 1985;89:732–735. - PubMed
    1. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5:215–229. doi: 10.1038/nri1573. - DOI - PubMed

LinkOut - more resources